<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02680106</url>
  </required_header>
  <id_info>
    <org_study_id>CIP0007</org_study_id>
    <nct_id>NCT02680106</nct_id>
  </id_info>
  <brief_title>Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites</brief_title>
  <acronym>SPINNER01</acronym>
  <official_title>EVALUATION OF THE SPINNER™ DEVICE FOR THE APPLICATION OF WOUND DRESSING: TREATMENT OF SPLIT SKIN-GRAFT DONOR SITES. A Prospective, Safety and Efficacy, Open Labeled, Two Arms, Randomized, Multi Center, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicast Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicast Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of safety and performance of the SPINNER device and wound dressing in the&#xD;
      treatment of donor-site wounds (DSW)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SPINNER is a hand held, portable electro-spinning device that produces personalized&#xD;
      in-situ nanofiber dressings for the treatment of external burns and wounds.&#xD;
&#xD;
      The dressing has non-adherence, high absorbance, bacterial protection, easy and pain-free&#xD;
      peel characteristics and shows excellent conformability and optimal coverage of the wound.&#xD;
&#xD;
      The objective of this study is to evaluate the safety and performance of the SPINNER device&#xD;
      and wound dressing in the treatment of donor-site wounds (DSW) at size of 10-200 cm2.&#xD;
&#xD;
      The study will include four sites in Israel:&#xD;
&#xD;
      Sheba Medical Center, Tel Hashomer Meir Medical Center, Kfar Saba Kaplan Medical Center,&#xD;
      Rehovot Souraski Medical Center, Tel Aviv&#xD;
&#xD;
      Study primary endpoints:&#xD;
&#xD;
        1. Dermal Safety&#xD;
&#xD;
        2. Wound healing and time to complete re-epithelialization at 1, 3, 5, 7, 14 and 21 days&#xD;
           post operation&#xD;
&#xD;
      Study secondary endpoints:&#xD;
&#xD;
        1. Ease of use&#xD;
&#xD;
        2. Pain assessment at 1, 3, 5, 7, 14 and 21 days post operation&#xD;
&#xD;
        3. Infection assessment from 3 days post operation up to 21 days&#xD;
&#xD;
        4. Device related adverse events of the SPINNER device and wound dressing&#xD;
&#xD;
      Extended exploratory follow up:&#xD;
&#xD;
      Assessment of itching and scarring from wound closure time and up to 12 months follow up with&#xD;
      an optional further examination at 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dermal safety (Draize) score</measure>
    <time_frame>1-21 days</time_frame>
    <description>Change in Draize score from procedure day to day 21</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in wound healing</measure>
    <time_frame>1-21 days</time_frame>
    <description>Change in wound healing in cm2 from procedure day to day 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ease of use</measure>
    <time_frame>21 days</time_frame>
    <description>Ease of use will be assessed (questionnaire) by the users whenever the SPINNER is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pain</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of pain (VAS scale 0-10) at 1, 3, 5, 7, 14 and 21 days post operation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of infection</measure>
    <time_frame>21 days</time_frame>
    <description>Assessment of infection (questionnaire) from 3 days post operation up to 21 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Wound of Skin</condition>
  <arm_group>
    <arm_group_label>SPINNER</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this arm will be treated with the SPINNER dressing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JELONET</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in this arm will be treated with JELONET dressing, regarded as the standard of current care for split-skin donor-site wounds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPINNER</intervention_name>
    <description>The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous dressing is thus created.</description>
    <arm_group_label>SPINNER</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JELONET</intervention_name>
    <description>The patient's DSW will be dressed by JELONET</description>
    <arm_group_label>JELONET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient is ≥ 18 years old at enrolment. Both genders.&#xD;
&#xD;
          -  Patients with donor site wound, size of 10-200 cm2, located in the thigh after partial&#xD;
             thickness skin-graft&#xD;
&#xD;
          -  The patient is able and willing to comply with study procedures and give written&#xD;
             informed consent prior to enrollment in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known or suspected systemic infection&#xD;
&#xD;
          -  Any known sensitivity to components/products used in this study&#xD;
&#xD;
          -  Use of penicillamine, corticosteroid or immunosuppressive medication within two months&#xD;
             prior to enrollment, or current use of nonsteroidal anti- inflammatory agents which&#xD;
             cannot be discontinued, or who is likely to be prescribed these medications or any&#xD;
             other medications known to adversely affect wound healing during study participation&#xD;
&#xD;
          -  Major uncontrolled systemic disorders such as hepatic, renal, neurologic, or&#xD;
             endocrinologic disorders.&#xD;
&#xD;
          -  Patients undergoing repeat skin graft harvesting at the same donor site&#xD;
&#xD;
          -  Patients with burns of more than 15% TBSA&#xD;
&#xD;
          -  Requires immersion hydrotherapy at any time during study participation&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Skin disorders such as psoriasis, pemphigus, Toxic Epidermal Necrolysis (TEN),&#xD;
             Stevens-Johnson Syndrome (SJS), pyoderma gangrenosum and other exfoliative disorders&#xD;
&#xD;
          -  Terminal patients&#xD;
&#xD;
          -  Soldiers&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Female patients who are pregnant or nursing, or of childbearing potential and are not&#xD;
             using adequate contraception&#xD;
&#xD;
          -  Participation in another clinical trial within 30 days prior to the Screening Visit or&#xD;
             during this study.&#xD;
&#xD;
          -  Psychiatric patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moti Harats, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burn Unit, Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Hospital</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2016</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nanofibers</keyword>
  <keyword>Dressing</keyword>
  <keyword>Donor site</keyword>
  <keyword>Polycaprolactone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

